Accelerate development of your therapeutics pipeline
Recombinant proteins are often the molecule of choice for creating innovative therapeutics. It’s often said that ‘the product is the process’ for recombinant proteins because of the challenges involved in creating a commercially scalable manufacturing strain. Requirements include an efficient but not excessively complex process; delivery of a regulatory compliant, high quality protein; reliable provision of batches for preclinical and clinical testing to meet strict development program timelines; and a competitive final cost of goods.
Phenotypeca’s QTL technology does all these things. It enables us to breed optimised strains that standard methods cannot deliver in a timely and reliable manner. Uniquely, QTL technology can deliver multi-parameter targeted optimisation that harnesses the power of the entire production strain genome.
Because Phenotypeca’s patent estate prevents competitors from developing rival recombinant proteins with similar advantages, partnering with us enables you to entrench your end product’s market dominance and drive revenue growth over the longer term.
Our work to lower the cost of certain vaccines supported by the Bill & Melinda Gates Foundation has demonstrated that our approach can deliver optimised strains much faster and more reliably than standard methods – and at a much lower cost. Crucially, everything we do is designed to enable manufacturing at scale while minimising the quantity of plant required and using safe, sustainable, animal-free bioprocesses without any toxic chemicals or antibiotics.
Collaborate with us
If your target recombinant protein therapeutic is at the discovery stage, Phenotypeca can create a bespoke optimised manufacturing process to deliver a commercial solution that also meets all the needs of your development cycle. If you intend to create and customise a recombinant protein with market-leading potential, you should get in contact.